TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
TG Therapeutics (NASDAQ:TGTX) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, NY. The company's Chairman and CEO, Michael S. Weiss, will engage in a fireside chat on Monday, September 8, 2025, at 10:30am ET.
Investors can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website at http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ:TGTX) ha annunciato la sua partecipazione alla 27ª H.C. Wainwright Annual Global Investment Conference a New York, NY. Il Presidente e CEO dell'azienda, Michael S. Weiss, prenderà parte a un fireside chat lunedì 8 settembre 2025 alle 10:30 ET.
Gli investitori potranno seguire la presentazione in diretta streaming dalla pagina Eventi nella sezione Investors & Media del sito di TG Therapeutics all'indirizzo http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ:TGTX) anunció su participación en la 27.ª Conferencia Anual Global de Inversiones H.C. Wainwright en Nueva York, NY. El presidente y CEO de la compañía, Michael S. Weiss, participará en un fireside chat el lunes 8 de septiembre de 2025 a las 10:30 ET.
Los inversores podrán ver la presentación en una transmisión en vivo desde la página Eventos en la sección Investors & Media del sitio web de TG Therapeutics en http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ:TGTX)는 뉴욕에서 열리는 제27회 H.C. Wainwright 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Michael S. Weiss가 2025년 9월 8일 월요일 동부시간 오전 10시 30분에 파이어사이드 채팅에 참석합니다.
투자자들은 TG Therapeutics 웹사이트의 Investors & Media 섹션 내 Events 페이지(http://ir.tgtherapeutics.com/events)를 통해 발표를 라이브 웹캐스트로 시청할 수 있습니다.
TG Therapeutics (NASDAQ:TGTX) a annoncé sa participation à la 27e conférence annuelle mondiale H.C. Wainwright à New York, NY. Le président-directeur général de la société, Michael S. Weiss, prendra part à un fireside chat le lundi 8 septembre 2025 à 10h30 ET.
Les investisseurs pourront suivre la présentation en webcast en direct depuis la page Événements de la rubrique Investors & Media du site de TG Therapeutics à l'adresse http://ir.tgtherapeutics.com/events.
TG Therapeutics (NASDAQ:TGTX) gab bekannt, dass das Unternehmen an der 27. H.C. Wainwright Annual Global Investment Conference in New York, NY, teilnimmt. Der Vorsitzende und CEO, Michael S. Weiss, wird an einem Fireside Chat am Montag, den 8. September 2025, um 10:30 Uhr ET teilnehmen.
Investoren können die Präsentation per Live-Webcast über die Seite "Events" im Bereich Investors & Media auf der Website von TG Therapeutics unter http://ir.tgtherapeutics.com/events verfolgen.
- None.
- None.
Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 – 10, 2025. The fireside chat is scheduled to take place on Monday, September 8, 2025, at 10:30am ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) in Europe, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, Swissmedic in Switzerland, and Australia’s Therapeutic Goods Administration (TGA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) presenting at the H.C. Wainwright Conference 2025?
Who will represent TG Therapeutics at the H.C. Wainwright Conference 2025?
How can investors watch TG Therapeutics' presentation at the H.C. Wainwright Conference?
Where is the H.C. Wainwright Global Investment Conference 2025 being held?
